2-(3,5-dibromo-4-hydroxyphenyl)-2-oxoacetaldehyde | 1191248-82-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(3,5-dibromo-4-hydroxyphenyl)-2-oxoacetaldehyde
• CAS: 1191248-82-4
• 化学式: C₈H₄Br₂O₃
• 分子量: 307.926
• InChiKey: HQXDTKPEJKYKJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(3,5-dibromo-4-hydroxyphenyl)-2-oxoacetaldehyde 在 羟胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 0.67h， 生成 2-(3,5-dibromo-4-hydroxyphenyl)-2-oxoacetaldehyde oxime
  参考文献：
  名称：

  Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives

  摘要：

  本发明涉及用于治疗动物患病的组合物和方法，该疾病对通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括表1-14中列出的那些化合物或被I-XII公式所包含的化合物）或其组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽作出反应，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊性肾病的方法。

  公开号：

  US20090318429A1
• 作为产物：
  描述：

  3',5'-二溴-4'-羟基苯乙酮 在 selenium(IV) oxide 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 2-(3,5-dibromo-4-hydroxyphenyl)-2-oxoacetaldehyde
  参考文献：
  名称：

  四吡嗪并卟啉镁：调节红色荧光pH指示剂的p K a †

  摘要：

  镁（II）tetrapyrazinoporphyrazines（TPyzPzs）是优异的红色荧光团（λ ˚F〜663纳米，Φ ˚F〜0.53在THF中）。在这项工作中，准备了一系列带有一个或两个酚取代基的不对称TPyzPzs的镁（II）配合物。酚部分的适当取代可调节其p K a在5.5至13的范围内。酚基团在较高pH值下的去质子化会在大环中诱导强供体（酚盐），从而导致这些指示剂的红色荧光的pH依赖性猝灭。在将TPyzPzs掺入两种乳状液和脂质体两种输送系统后，水溶液中的pH感测得到了证实。后者还充当生物膜的简单模型。最后，通过将TPyzPz指示剂和亲脂性pH不敏感的BODIPY染料掺入脂质体中，构建了波长比探针。TPyzPzs的合成前体，即取代的2,3-二嗪吡嗪，也代表了供体-受体系统，肉眼很容易看到吸收光谱的pH依赖性变化。

  DOI：

  10.1039/c9dt00381a

文献信息

• Unexplored reactivity of 2-oxoaldehydes towards Pictet–Spengler conditions: concise approach to β-carboline based marine natural products
  作者：Narsaiah Battini、Anil K. Padala、Nagaraju Mupparapu、Ram A. Vishwakarma、Qazi Naveed Ahmed

  DOI：10.1039/c4ra01387e

  日期：——

  Novel reactions under Pictet–Spengler conditions between tryptophan methyl ester/tryptamine and 2-oxoaldehydes have been developed and successfully utilized for the total synthesis of Merinacarboline (A and B), Eudistomin Y1, Pityriacitrin B, Pityriacitrin, Fascaplysin and analogues.

  在Pictet–Spengler条件下，开发了色氨酸甲酯/色胺与2-氧代醛之间的新型反应，并成功应用于Merinacarboline（A和B）、Eudistomin Y1、Pityriacitrin B、Pityriacitrin、Fascaplysin及其类似物的全合成。
• Compounds, Compositions and Methods Comprising Triazine Derivatives
  申请人：Russell Michael Geoffrey Neil

  公开号：US20090264433A1

  公开（公告）日：2009-10-22

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or encompassed by formulas I-II) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及治疗动物疾病的组合物和方法，该疾病对通过向需要的哺乳动物施用本文中定义的化合物的有效量（包括表1中列出的那些化合物或由公式I-II包围的化合物）或其组合物进行抑制功能性囊性纤维化跨膜传导调节器（CFTR）多肽而产生反应，从而治疗该疾病。本发明特别涉及治疗腹泻和多囊性肾病的方法。
• Compounds, compositions and methods comprising heteroaromatic derivatives
  申请人：Doyle Kevin James

  公开号：US20100144733A1

  公开（公告）日：2010-06-10

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物体内对抑制功能性囊性纤维化跨膜传导调节因子（CFTR）多肽敏感的疾病的组合物和方法，通过向需要治疗该疾病的哺乳动物中投与本文所定义的化合物的有效量（包括表1-14中列出的化合物或公式I-XII所包含的化合物）或其组合物，从而治疗该疾病。本发明特别涉及治疗腹泻和多囊肾病的方法。
• [EN] COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING TRIAZINE DERIVATIVES<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS À BASE DE DÉRIVÉS DE TRIAZINE
  申请人：INST ONEWORLD HEALTH

  公开号：WO2009131958A2

  公开（公告）日：2009-10-29

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Table 1 or encompassed by formulas I-II) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.
• Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives
  申请人：Doyle Kevin James

  公开号：US20090318429A1

  公开（公告）日：2009-12-24

  The present invention relates to compositions and methods for treating a disease in an animal, which disease is responsive to inhibiting of functional cystic fibrosis transmembrane conductance regulator (CFTR) polypeptide by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-14 or encompassed by formulas I-XII) or compositions thereof, thereby treating the disease. The present invention particularly, relates to a method of treating diarrhea and polycystic kidney disease.

  本发明涉及用于治疗动物患病的组合物和方法，该疾病对通过向需要的哺乳动物投予本文所定义的化合物的有效量（包括表1-14中列出的那些化合物或被I-XII公式所包含的化合物）或其组合物来抑制功能性囊性纤维化跨膜传导调节蛋白（CFTR）多肽作出反应，从而治疗该疾病。本发明特别涉及一种治疗腹泻和多囊性肾病的方法。